Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17132825 | Methods for treating inflammatory skin conditions | December 2020 | February 2022 | Allow | 14 | 1 | 1 | Yes | No |
| 17130769 | GHB DOSING | December 2020 | January 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17126810 | PROCESS FOR THE PREPARATION OF BAKUCHIOL COMPOSITION SUBSTANTIALLY FREE OF FURANOCOUMARIN IMPURITIES | December 2020 | February 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17119482 | MEDICAL TREATMENTS BASED ON ANAMORELIN | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17115416 | NOVEL METHODS | December 2020 | February 2024 | Allow | 38 | 2 | 1 | No | No |
| 17113633 | METHODS FOR TREATING GAUCHER DISEASE | December 2020 | December 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17055349 | Disease Modifying Methods For Treating Neurodegenerative Diseases Using Nootropic Agents | November 2020 | February 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17094396 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | November 2020 | October 2023 | Allow | 35 | 1 | 1 | No | No |
| 17087971 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | November 2020 | March 2021 | Allow | 4 | 1 | 1 | Yes | No |
| 17080499 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION | October 2020 | March 2023 | Allow | 28 | 1 | 0 | No | No |
| 17080471 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy | October 2020 | March 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17065367 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | October 2020 | April 2022 | Allow | 18 | 0 | 0 | Yes | No |
| 16948813 | Mirtazapine for use in medication overuse headache based on tension-type headache | October 2020 | September 2021 | Allow | 12 | 2 | 0 | Yes | No |
| 17026413 | DEUTERATED ANALOGS OF D-BETA-HYDROXYBUTYRIC ACID AND USES THEREOF | September 2020 | January 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17012526 | OPTIMIZING VOLATILE ENTOURAGES IN DRY FLOWERING PLANT MIXTURES | September 2020 | January 2022 | Allow | 16 | 3 | 1 | Yes | No |
| 17011715 | CANNABIDIOL PREPARATIONS AND ITS USES | September 2020 | August 2021 | Allow | 11 | 0 | 2 | Yes | No |
| 15733538 | Pharmaceutical formulation for use in the treatment of depressive and anxiety disorders | August 2020 | January 2022 | Allow | 17 | 0 | 0 | No | No |
| 16999015 | MIF MODULATORS | August 2020 | January 2023 | Abandon | 29 | 1 | 0 | No | No |
| 16996082 | SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS | August 2020 | September 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16994940 | TREATMENT OF OCULAR DISEASES WITH OPHTHALMIC TAPINAROF COMPOSITIONS | August 2020 | February 2022 | Abandon | 18 | 0 | 0 | No | No |
| 16968793 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | August 2020 | June 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16965248 | NOVEL USES | July 2020 | April 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16935452 | TREATMENT OF OCULAR DISEASES WITH OPHTHALMIC TAPINAROF COMPOSITIONS | July 2020 | February 2022 | Abandon | 19 | 0 | 0 | No | No |
| 16935489 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | July 2020 | October 2020 | Allow | 3 | 0 | 1 | Yes | No |
| 16934715 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | July 2020 | June 2023 | Allow | 34 | 1 | 1 | No | No |
| 16922893 | NOVEL METHODS | July 2020 | July 2024 | Abandon | 48 | 4 | 0 | No | No |
| 16920267 | TREATMENT OF A HEMATOLOGIC MALIGNANCY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | July 2020 | October 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16959350 | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | June 2020 | June 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16903551 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | June 2020 | March 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16890044 | TOPICAL DUTASTERIDE EMULSIONS FOR TREATING ENDOCRINE THERAPY-INDUCED ALOPECIA | June 2020 | February 2022 | Allow | 20 | 3 | 1 | Yes | No |
| 16888716 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF ACUTE RADIATION SYNDROME AND OTHER RADIATION EXPOSURE | May 2020 | April 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 16768346 | USE OF TRIETHYLENETETRAMINE (TETA) FOR THE THERAPEUTIC INDUCTION OF AUTOPHAGY | May 2020 | June 2023 | Abandon | 37 | 3 | 1 | Yes | No |
| 16886730 | TOPICAL TREATMENT OF HERPES INFECTIONS | May 2020 | November 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16883747 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | May 2020 | April 2022 | Allow | 23 | 1 | 1 | No | No |
| 16881354 | INHALABLE FORMULATION OF A SOLUTION CONTAINING VILANTEROL TRIFENATATE AND UMECLIDINIUM BROMIDE | May 2020 | March 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16763177 | METHODS FOR INDUCING PUPIL DILATION | May 2020 | April 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16871748 | METHOD OF TREATING SELECTED PATIENT POPULATION EXPERIENCING DRAVET SYNDROME | May 2020 | February 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16762233 | COMPOSITIONS AND METHODS FOR AQUACULTURING | May 2020 | February 2024 | Allow | 45 | 2 | 1 | No | No |
| 16760159 | Cannabinoid Formulations | April 2020 | June 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16756689 | TRANSDERMAL FORMULATION FOR DELIVERY OF HYDROPHOBIC COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16827622 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | March 2020 | October 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16813436 | METHODS OF TREATING SUBJECTS HAVING DIABETES WITH CHRONIC KIDNEY DISEASE | March 2020 | November 2021 | Allow | 20 | 2 | 0 | Yes | Yes |
| 16644432 | HYDROGEN-CONTAINING COMPOSITION | March 2020 | October 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16798134 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | February 2020 | March 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16794905 | Arginase Inhibitors as Therapeutics | February 2020 | March 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16786846 | Pesticidal Compositions and Related Methods | February 2020 | June 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16783956 | RACEMIC BETA-HYDROXYBUTYRATE MIXED SALT-ACID COMPOSITIONS AND METHODS OF USE | February 2020 | February 2021 | Allow | 12 | 2 | 1 | No | No |
| 16782259 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | February 2020 | February 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16779015 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | January 2020 | December 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16635199 | ANTI-AGING OR SKIN-REGENERATING COMPOSITION COMPRISING PIPERONYLIC ACID AS EFFECTIVE INGREDIENT | January 2020 | May 2022 | Allow | 27 | 0 | 0 | Yes | No |
| 16752961 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | January 2020 | January 2022 | Allow | 24 | 1 | 0 | No | No |
| 16751969 | POLYMORPHIC FORM OF TG02 FOR TREATING CANCER | January 2020 | August 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16752119 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | January 2020 | November 2021 | Allow | 21 | 0 | 1 | Yes | No |
| 16749266 | PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF | January 2020 | April 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16749347 | PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF | January 2020 | January 2022 | Allow | 24 | 1 | 0 | No | No |
| 16738276 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | January 2020 | October 2021 | Allow | 22 | 2 | 1 | Yes | No |
| 16737707 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | January 2020 | February 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16736609 | METHODS FOR TREATING DEPENDENCE | January 2020 | June 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16732173 | METHOD OF TREATING AN INFLAMMATORY OR INFECTIOUS DISEASE | December 2019 | February 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16718343 | EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION | December 2019 | August 2021 | Allow | 20 | 0 | 1 | Yes | No |
| 16703340 | HISTONE DEACETYLASE INHIBITORS | December 2019 | September 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16698197 | Cannabinoid Compositions | November 2019 | May 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16697420 | METHOD FOR ENHANCING WOUND HEALING BY ADMINISTRATING ADENINE | November 2019 | February 2022 | Allow | 26 | 3 | 0 | No | No |
| 16694384 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | November 2019 | October 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16688400 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | November 2019 | January 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 16678806 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | November 2019 | June 2020 | Allow | 7 | 0 | 0 | Yes | No |
| 16660994 | SOLUBLE C5aR ANTAGONISTS | October 2019 | November 2021 | Allow | 25 | 1 | 1 | No | No |
| 16601323 | A19-144, A2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITOR COMPOSITIONS AND METHOD FOR ANTI-SEIZURE THERAPY | October 2019 | June 2020 | Allow | 8 | 0 | 0 | Yes | No |
| 16590703 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | October 2019 | September 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16578084 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | September 2019 | October 2021 | Allow | 25 | 1 | 0 | No | No |
| 16576336 | Ibuprofen for Topical Administration | September 2019 | January 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16494011 | PHARMACEUTICAL COMPOSITION OF ORAL SUSPENSION OF ANTI-NEOPLASTIC ALKYLATING AGENTS | September 2019 | August 2021 | Allow | 23 | 0 | 1 | Yes | No |
| 16564694 | Methods for Treatment of Fabry Disease | September 2019 | September 2021 | Allow | 25 | 2 | 0 | No | No |
| 16552537 | MAP KINASE MODULATORS AND USES THEREOF | August 2019 | June 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16551570 | COMPOSITIONS AND METHODS FOR DELIVERING CANNABIDIOL AND KETONE BODIES | August 2019 | May 2021 | Allow | 21 | 2 | 1 | Yes | No |
| 16543763 | MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES | August 2019 | November 2020 | Abandon | 15 | 0 | 1 | No | No |
| 16532985 | COMPOSITIONS COMPRISING CANNABINOIDS FOR TREATMENT OF NAUSEA, VOMITING, EMESIS, MOTION SICKNESS OR LIKE CONDITIONS | August 2019 | January 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16533283 | ANTIVIRAL TREATMENTS | August 2019 | May 2022 | Allow | 34 | 3 | 0 | No | No |
| 16531446 | FEEDING DETERRENCE OF PESTS SUCH AS HEMIPTERA, LEPIDOPTERA AND COLEOPTERA | August 2019 | October 2021 | Allow | 27 | 2 | 1 | No | No |
| 16530274 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | August 2019 | November 2019 | Allow | 3 | 0 | 0 | No | No |
| 16482656 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | July 2019 | February 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16528032 | METHODS OF TREATING OVERACTIVE BLADDER USING TROSPIUM | July 2019 | May 2022 | Allow | 33 | 4 | 0 | Yes | No |
| 16526662 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | July 2019 | January 2021 | Allow | 18 | 2 | 0 | Yes | No |
| 16526365 | SUBSTANTIALLY SODIUM FREE DICLOFENAC POTASSIUM ORAL SOLUTIONS | July 2019 | May 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16525176 | COMPOSITION AND METHOD FOR TREATING PROSTATE DISORDERS | July 2019 | December 2020 | Allow | 16 | 1 | 0 | Yes | No |
| 16519605 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH | July 2019 | November 2022 | Abandon | 40 | 2 | 1 | No | Yes |
| 16455269 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | June 2019 | March 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16453393 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | June 2019 | December 2020 | Allow | 18 | 1 | 1 | Yes | No |
| 16444367 | ICARISIDE COMPOUND, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF | June 2019 | July 2021 | Allow | 25 | 2 | 0 | No | No |
| 16467639 | USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME | June 2019 | January 2023 | Allow | 44 | 4 | 0 | Yes | No |
| 16461614 | LACTAM COMPOSTIONS | May 2019 | March 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16323106 | COMPOSITION FOR TREATING ADULT T CELL LEUKEMIA/LYMPHOMA AND METHOD FOR PRODUCING SAME | May 2019 | March 2022 | Allow | 37 | 2 | 1 | No | No |
| 16405521 | MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS | May 2019 | October 2020 | Abandon | 18 | 1 | 0 | No | No |
| 16402454 | 1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AS INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | May 2019 | July 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16400132 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | May 2019 | February 2020 | Allow | 10 | 0 | 0 | Yes | No |
| 16396321 | SOLUBILIZED CANNABINOID POWDERS | April 2019 | August 2021 | Abandon | 28 | 2 | 1 | Yes | Yes |
| 16394431 | COMPOSITION FOR IMPROVING DECREASED ABSORPTION IN DIGESTIVE TRACT, AND COMPOSITION FOR PROMOTING ABSORPTION IN DIGESTIVE TRACT | April 2019 | February 2023 | Abandon | 45 | 6 | 1 | Yes | No |
| 16385350 | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury | April 2019 | December 2021 | Allow | 32 | 2 | 1 | No | No |
| 16378422 | BICYCLIC ANALGESIC COMPOUNDS | April 2019 | September 2020 | Abandon | 17 | 0 | 1 | No | No |
| 16370443 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | March 2019 | September 2019 | Allow | 6 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JAVANMARD, SAHAR.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JAVANMARD, SAHAR works in Art Unit 1627 and has examined 747 patent applications in our dataset. With an allowance rate of 57.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner JAVANMARD, SAHAR's allowance rate of 57.4% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JAVANMARD, SAHAR receive 1.55 office actions before reaching final disposition. This places the examiner in the 25% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JAVANMARD, SAHAR is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +48.2% benefit to allowance rate for applications examined by JAVANMARD, SAHAR. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.4% of applications are subsequently allowed. This success rate is in the 63% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 45.8% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 81.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 62.7% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.0% of allowed cases (in the 75% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.